Plants - Drugs Mind - Spirit Freedom - Law Arts - Culture Library  
Erowid References Database
Nichols DE, Johnson MW, Nichols CD. 
“Psychedelics as Medicines: An Emerging New Paradigm”. 
Clin Pharmacol Ther. 2017 Feb 26;101(2):209-219.
Scientific interest in serotonergic psychedelics (e.g., psilocybin and LSD; 5-HT2A receptor agonists) has dramatically increased within the last decade. Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that these compounds have potential efficacy against inflammatory diseases through novel mechanisms, with potential advantages over existing antiinflammatory agents. We propose that psychedelics exert therapeutic effects for psychiatric disorders by acutely destabilizing local brain network hubs and global network connectivity via amplification of neuronal avalanches, providing the occasion for brain network resetting after the acute effects have resolved. Antiinflammatory effects may hold promise for efficacy in treatment of inflammation-related nonpsychiatric as well as potentially for psychiatric disorders. Serotonergic psychedelics operate through unique mechanisms that show promising effects for a variety of intractable, debilitating, and lethal disorders, and should be rigorously researched.
Notes # : Inflammation discussion super interesting.
Comments and Responses to this Article
Status: display
Jan 28, 2017 15:43
interesting new Hypothesis of Antiinflammatory Effect #

"In summary, animal models of human diseases indicate that psychedelics in general, and (R)-DOI in particular, may be an effective therapy for asthma, atherosclerosis, coronary artery disease, and inflammatory bowel disease. There are several other inflammatory conditions that we believe also may benefit from (R)-DOI therapy, including rheumatoid arthritis and diabetes."

"If continuing clinical studies further validate the use of psychedelic-assisted therapy for all of the above-discussed CNS indications, it begs the question, “How can the same single treatment approach lead to improvement in such a diverse range of dysfunctions?” This question deserves serious consideration, which we shall now attempt to address, and is at the core of what is suggested in the title as “a new paradigm.” We emphasize that the ideas to be discussed here represent untested hypotheses, but are consistent with presently known results."
Submit Comment
[ Cite HTML ]